Magellan Asset Management Ltd Makes New $53.11 Million Investment in Thermo Fisher Scientific Inc. $TMO

Magellan Asset Management Ltd bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 105,936 shares of the medical research company’s stock, valued at approximately $53,112,000. Thermo Fisher Scientific comprises approximately 1.2% of Magellan Asset Management Ltd’s investment portfolio, making the stock its 29th largest position.

Several other hedge funds also recently modified their holdings of TMO. Brighton Jones LLC lifted its stake in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $170,000. Raymond James Financial Inc. lifted its holdings in shares of Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after acquiring an additional 53,542 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after acquiring an additional 2,262 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.0%

Thermo Fisher Scientific stock opened at $629.02 on Monday. The company’s 50-day moving average price is $542.53 and its two-hundred day moving average price is $509.19. The stock has a market cap of $232.58 billion, a price-to-earnings ratio of 33.84, a PEG ratio of 2.56 and a beta of 0.84. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. The trade was a 54.85% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 63,493 shares of company stock valued at $37,657,681. Corporate insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

TMO has been the subject of a number of recent research reports. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Royal Bank Of Canada boosted their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. Finally, Wolfe Research began coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.